Phase 2 N=19 Dextromethorphan in Fibromyalgia
Fibromyalgia
Primary: Daily Self-reported Pain Severity — 41.09; 45.55 score/day — p=0.146
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=453 A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline Over Time in CDR-SB Score — 0.60; 0.66; 0.44; 0.63 score on a scale — p=0.740
Phase 2 N=34 A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Subjects With Reduction in Targeted Ichthyosis Severity Using the Visual Index for Ichthyosis Severity Measurement — 4; 7; 4 Participants
Phase 2 N=57 Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Granulomatosis With Polyangiitis (GPA) · Microscopic Polyangiitis (MPA)
Primary: Percentage of Subjects Achieving Clinical Response — 16; 22; 10 Participants
Phase 2 N=35 Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
Head and Neck Cancer · Human Papilloma Virus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 15; 9; 11; 4 Participants
Phase 2 N=31 Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Gastric Cardia Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Stage IB Gastric Cancer AJCC v7
Primary: Pathological Complete Response (PathCR) Rate — 22.6 percentage of patients
Phase 2 N=118 Open-Label Extension and Safety Study of Talazoparib
Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Emergent Treatment Related AEs and…
Phase 2 N=66 An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
Jansky-Bielschowsky Disease · Batten Disease · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Primary: Probability of Unreversed 2-point Decline in Motor-language (ML) Score or Score of 0 — 0.13; 0.48; 0.22; 0.91 Probability of decline — p=<0.0001
Phase 2 N=88 Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
Psoriasis
Primary: Percentage of Participants With Success Rate 1 (SR1) at Week 8 — 4.5; 0.0 percentage of participants
Phase 2 N=83 Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Complete Clearance Rate — 7; 9 Participants
Phase 2 N=1,301 Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
Malaria
Primary: Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 — 15; 14; 15; 15 Participants
Phase 2 N=52 AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)
Breast Cancer
Primary: Number of Participants With Serious Adverse Events (SAEs) — 10 Participants
Phase 2 N=26 GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs)-Part 1 — 0; 0; 0; 0 Participants
Phase 2 N=88 Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
Renal Cell Carcinoma, Metastatic
Primary: Overall Survival (OS) - Days (FAS) — 323; 282; 1270; 1099 days — p=0.964
Phase 2 N=29 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Adult Angiosarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: PFS Rate — 54.6 percentage of patients